Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618534 · ClinicalTrials.gov registry record · Phase 2
Azithromycin for Meningococcal Carriage
A Phase 2 study of Meningococcal Infections, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,120
- Enrollment target
- 1
- Study location
NCT06618534: Recruiting Phase 2 study of Meningococcal Infections, sponsored by Emory University.
NCT06618534 is a Phase 2 study of Meningococcal Infections that is actively recruiting participants, run by Emory University. The registered enrollment target is 1,120 participants, above the 541-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (107% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06618534, a Phase 2 study of Meningococcal Infections, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
Primary Outcome
Eradication of N. meningitidis carriage is defined as positive culture at the second visit (immediately prior to azithromycin administration) and negative culture approximately 2 weeks after antibiotic administration.
Conditions Studied
Interventions
- DRUG Azithromycin
Study Locations (1)
Georgia
- Hope Clinic of the Emory Vaccine Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,120 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06618534 shows while recruiting
NCT06618534 is an interventional study that assigns participants to a tested intervention. Its 1,120 participants enrollment target places it among the larger protocols in the corpus, above the 541-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (107% higher).
The record links to 1 condition, with Meningococcal Infections appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.
NCT06618534 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06618534 about?
NCT06618534 is a clinical study titled "Azithromycin for Meningococcal Carriage". The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
What is the current status of trial NCT06618534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,120 participants. The study started on 2024-11-12. Estimated completion is 2026-05.
What conditions does trial NCT06618534 study?
This clinical trial studies the following conditions: Meningococcal Infections.
What interventions are being tested in trial NCT06618534?
The interventions under investigation include: Azithromycin (DRUG).
Who is sponsoring clinical trial NCT06618534?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618534 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningococcal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
-
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
COMPLETED · Phase 1
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- NCT05438329 · 1,123 participants · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI